The Diabetic Macular Edema drugs in development market research report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Diabetic Macular Edema. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued products.
GlobalData tracks 146 drugs in development for Diabetic Macular Edema by 118 companies/universities/institutes. The top development phase for Diabetic Macular Edema is preclinical with 62 drugs in that stage. The Diabetic Macular Edema pipeline has 143 drugs in development by companies and two by universities/ institutes. Some of the companies in the Diabetic Macular Edema pipeline products market are: F. Hoffmann-La Roche, AffaMed Therapeutics US and ANBITION.
The key targets in the Diabetic Macular Edema pipeline products market include Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, and Placenta Growth Factor.
The key mechanisms of action in the Diabetic Macular Edema pipeline product include Vascular Endothelial Growth Factor A Inhibitor with 31 drugs in Pre-Registration. The Diabetic Macular Edema pipeline products include 11 routes of administration with the top ROA being Intravitreal and 13 key molecule types in the Diabetic Macular Edema pipeline products market including Monoclonal Antibody, and Small Molecule.
Diabetic Macular Edema overview
Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if left untreated. Risk factors include age and diabetes.
For a complete picture of Diabetic Macular Edema’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
